Drug Development

Two companion trials published in Nature Medicine show oral FMT capsules raised immunotherapy response rates to 80% in lung cancer and 75% in melanoma, while reducing toxic side effects in kidney cancer.

The first once-weekly treatment for achondroplasia is now commercially available in the United States after Ascendis Pharma secured orphan drug exclusivity through 2033.

Two bipartisan Senate bills would create a VA Office of Novel Therapeutics and fund psychedelic research centers, while states enact their own laws and Phase 3 trials advance.

Full results from Novo Nordisk's EVOKE and EVOKE+ trials, published in The Lancet, show oral semaglutide had no effect on cognitive decline over two years despite reducing key cerebrospinal fluid markers of neuroinflammation and tau pathology by roughly 10 percent.

University of Edinburgh researchers engineered bacteria to transform PET plastic into levodopa, a frontline Parkinson's medication, achieving 84 percent conversion from industrial waste in a proof-of-concept published in Nature Sustainability.

The SWOG S2419 BioFront study is the first large-scale randomized trial testing whether a daily oral bacterial supplement can boost immunotherapy outcomes in advanced kidney cancer.

Australian biomanufacturing startup Cauldron Ferm has closed a $13.25 million Series A2 round to expand its continuous hyper-fermentation platform, which it claims reduces unit costs by up to 50 percent and capital expenditure by 45 percent compared to conventional batch processes.

Texas will fully fund a $50 million ibogaine trial through 11 universities after no drug company met partnership terms, targeting PTSD, addiction, and TBI in veterans.

The US government's health research agency has funded the first large-scale clinical trials testing whether rapamycin, semaglutide, and other repurposed drugs can slow biological aging in healthy adults, with results expected within three years.

A collaboration between VML, The Organoid Company, and Lab-Grown Leather Ltd. has produced the first handbag from material engineered using reconstructed Tyrannosaurus rex collagen sequences, but paleontologists challenge the project's scientific framing.

An Fc-engineered CD40 agonist injected into a single tumor triggered systemic immune responses that eliminated cancer across the body in two patients, with expanded trials now under way at Memorial Sloan Kettering and Duke.

The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist from Eli Lilly, for adults with obesity or overweight. It is the first new molecular entity approved under the National Priority Voucher program and the fastest NME approval since 2002.